DEVELOPMENT AND EVALUATION OF NANOSPONGES LOADED EXTENDED RELEASE TABLETS OF LANSOPRAZOLE

Dingwoke John Emeka Francis; Felix Sunday Yusuf

doi:10.22270/ujpr.v4i1.239

Dingwoke John Emeka Francis Department of Biochemistry, Ahmadu Bello University, Main Campus, P.M.B. 1054, Zaria, Kaduna State, Nigeria.
Felix Sunday Yusuf Business Continuity Solutions, Neuts, Nigeria.

10.22270/ujpr.v4i1.239

Keywords:

Entrapment efficiency, ethyl cellulose, HPMC, in-vitro drug release, lansoprazole,, nanosponges

Abstract

Objective: Nanosponges are tiny sponges with an average diameter below 1µm and consist of cavities filled with drug molecules. Lansoprazole is one of the classes of proton pump inhibitors, it reduces gastric acidity, and used in disorders such as gastric ulcer, duodenal ulcer and reflux oesophagitis.

Methods: In present study for extended delivery of lansoprazole at optimal concentration and to reduce the frequency of dosing and thus to increase patient convenience nanosponges loaded extended release tablets were prepared. Initially four different nanosponges formulations were prepared by solvent evaporation method and evaluated on various parameters. Ethyl cellulose was used as entrapping agent and dichloromethane as cross linking agent in various proportions and evaluated for powder flow properties, % yield, zeta potential, and in-vitro drug release characteristics. All five formulations were evaluated for thickness, hardness, friability, % drug content and in-vitro drug release.

Results: The % drug entrapment efficiency of the nanosponges was found to be best for the formulation NS1 and it was ranged from 68.86±0.10 to 88.66±0.5. All the formulations showed drug release for a period of 8 h.

Conclusion: From the results, it was found that all the evaluation results are within pharmacopoeial limits. From this study, we concluded feasibility of extended release of Lansoprazole through nanosponge loaded extended release tablets. Formulation of batch NT1, containing HPMC K30 was found to be optimum formulation.

Peer Review History:

Received 4 December 2018; Revised 13 January 2019; Accepted 1 March 2019; Available online 15 March 2019

Academic Editor: Dr. Gehan Fawzy Abdel Raoof Kandeel, Pharmacognosy Department, National Research Centre, Dokki, 12622, Giza, Egypt, gehankandeel9@yahoo.com

Received file: Reviewer's Comments:

Average Peer review marks at initial stage: 3/10

Average Peer review marks at publication stage:7.5/10

Reviewer(s) detail:

Prof. Dr. Kapil Kumar, Global Institute of Pharmaceutical Education and Research,
Kashipur, US Nagar, Uttarakhand, India, kapil5november@gmail.com

Kian Navaee, Shahre Daru Pharmaceutical Co., Iran, kian.navaee@chemist.com